#United States #Cervical Cancer #BD #Franklin Lakes #HPV Testing

BD's Simplified At-Home HPV Testing

In a significant step towards improving public health accessibility, BD (Becton, Dickinson and Company), a global leader in medical technology, has launched an innovative self-collection solution for HPV testing designed for markets beyond the United States. This groundbreaking technology is poised to make cervical cancer screening more accessible and efficient, reflecting BD's commitment to enhancing healthcare worldwide.

Streamlining the Process

The newly developed self-collection method simplifies the HPV testing process at home for patients. Unlike traditional collection methods that often require complex equipment or liquids, BD's solution allows for a safe, non-invasive collection experience using specialized swab technology. This advancement has been certified under the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe and is acknowledged by numerous other countries, ensuring widespread acceptance and reliability.

Once patients collect their samples, they can conveniently send them directly to the lab without worrying about storage complications. The swab's stability enables easy mailing, addressing logistical challenges that often hinder participation in cervical cancer screening programs. This innovation is particularly beneficial for underscreened populations, empowering individuals to take charge of their health from the comfort of their homes.

Leveraging Technology for Efficiency

At the laboratory level, the self-collected swab eliminates the need for manual sample preparation by clinical lab technologists, allowing them to concentrate on more complex and valuable tasks. Upon submission of a sample into the BD COR™ System, a fully automated process takes over. Sophisticated robotics manage the preparation, analysis, and reporting of results, ensuring that each sample is processed efficiently and accurately.

To enhance reliability, BD's solution incorporates an internal cellular control, minimizing manual touches and intervention. This design ensures that the specimen's integrity is maintained throughout the journey from collection to result reporting, delivering dependable and high-quality outcomes for patients.

Global Efforts for Cervical Cancer Screening

Nikos Pavlidis, the worldwide president of BD Diagnostic Solutions, expressed that this certification represents a critical leap in expanding access to cervical cancer screening across the globe. He stated, "By enabling fully automated processing of self-collected samples, we're helping laboratories improve efficiency while making it easier for underscreened individuals to engage in screening programs from the comfort of their homes."

Key Features of the New Technology

The IVDR-certified workflow introduces several advantageous features:

• - Onboard Rehydration Technology: This innovation removes the need for manual sample preparation, enhancing efficiency.
• - Safe and Dry Self-Collection: Patients can collect samples without the use of liquids or chemicals, simplifying the process.
• - User-Friendly Experience: The step-by-step process has been crafted to be intuitive, making it accessible for all patients.
• - Sample Stability: The swabs offer 30-day dry sample stability, withstanding variances in temperature and conditions, which is crucial for reliable lab results.
• - Barcode-Driven Workflow: The unified system handles both clinician-taken and self-collected samples, streamlining laboratory operations.

Future Commercial Availability

The BD Onclarity™ HPV Self-Collection with Onboard Rehydration Fully Automated Solution is anticipated to be commercially available in IVDR-recognized markets soon. This step aligns with broader public health objectives to expand cervical cancer screening access while simultaneously enhancing laboratory efficiency.

For further information about this innovative cervical cancer screening solution, please visit BD's webpage.

As a leader in the medical technology sector, BD tirelessly works to advance healthcare delivery and diagnostics globally. Their new self-collection solution for HPV testing is a testament to their ongoing commitment to improving health outcomes and addressing pressing public health challenges.

BD operates in nearly every country, collaborating with various organizations to enhance health accessibility and quality worldwide.